Skip to main content
. 2017 Jun 22;12(6):e0179680. doi: 10.1371/journal.pone.0179680

Fig 4. Risk ratio of hepatitis and chemotherapy disruption comparing antiviral prophylaxis with non-prophylaxis in HBsAg-positive lung cancer patients.

Fig 4